Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Advanced Medullary Thyroid Carcinoma
NCT01874873Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in medullary thyroid carcinoma (MTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression-Free Survival up to 48 months. Started Apr 2013; status: completed.
02
Drugs
anlotinib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT01874873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874873.